期刊
MOLECULAR CANCER THERAPEUTICS
卷 13, 期 12, 页码 2769-2783出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-14-0290
关键词
-
类别
资金
- Cancer Research UK [C30122/A11527, C30122/A15774]
- KCL Experimental Cancer Medicine Centre
- Cancer Research UK
- National Institute for Health Research
- Welsh Assembly Government
- HSC R&D Office for Northern Ireland
- Chief Scientist Office, Scotland
- CR UK/EPSRC/MRC/NIHR KCL/UCL Comprehensive Cancer Imaging Centre [C1519/A10331]
- Medical Research Council [MR/L023091/1]
- Dermatrust
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust
- King's College London
- KAPA-Privatstiftung Wien
- Academy of Medical Sciences (AMS) [AMS-SGCL10-Josephs] Funding Source: researchfish
- National Institute for Health Research [CL-2012-17-005] Funding Source: researchfish
Malignant melanoma is associated with poor clinical prognosis; however, novel molecular and immune therapies are now improving patient outcomes. Almost 50% of melanomas harbor targetable activating mutations of BRAF that promote RAS-RAF-MEK-ERK pathway activation and melanoma proliferation. Recent evidence also indicates that melanomas bearing mutant BRAF may also have altered immune responses, suggesting additional avenues for treatment of this patient group. The small molecule inhibitors selective for mutant BRAF induce significant but short-lived clinical responses in a proportion of patients, but also lead to immune stimulatory bystander events, which then subside with the emergence of resistance to inhibition. Simultaneous BRAF and MEK inhibition, and especially combination of BRAF inhibitors with new immunotherapies such as checkpoint blockade antibodies, may further enhance immune activation, or counteract immunosuppressive signals. Preclinical evaluation and ongoing clinical trials should provide novel insights into the role of immunity in the therapy of BRAF-mutant melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据